Nation-wide study will measure the impact of comprehensive genomic profiling on access to, and uptake of, personalised medicines and on clinical outcomes for patients across Belgium
GOSSELIES, FEBRUARY 4, 2021 – Today, the Belgian Society of Medical Oncology (BSMO) announced a new national pilot to evaluate the use of comprehensive genomic profiling (CGP) in 864 patients with advanced metastatic cancer. The BALLETT (Belgian Approach for Local Laboratory Extensive Tumor Testing) study will recruit patients from 12 participating sites to be offered CGP from one of nine NGS laboratories across Belgium. Data from CGP will be used to determine the best therapeutic options for patients through access to targeted medicines with the aim of improving clinical outcomes in advanced cancer. The study will begin next month.
CGP uses next-generation sequencing (NGS) to analyse hundreds of genes and biomarkers in tissue and blood samples and detect those that are clinically relevant in driving cancer growth. Illumina will provide its CGP panel, TruSight™ Oncology 500 (TSO500), as well as NovaSeq™6000 and NextSeq™ sequencing platforms for the study. Clinical interpretation of the sequencing data will be carried out using OncoDNA Clinical Decision Support Platform OncoKDM®.
“Giving access to CGP and clinical decision support in clinical routine is key to improve patient journey and personalise cancer care. OncoKDM® is designed to guide oncologists through the selection of the most appropriate treatments available for their cancer patients. Supported by a proprietary curated database that is daily updated with the latest therapeutic advances in precision oncology, it turns complex NGS and other biomarker data into clear and personalized clinical decision reports. We are delighted to support BSMO in this landmark project and to offer all participating sites a seamless experience with our OncoKDM® software”, said Jean-Pol Detiffe, OncoDNA’s Chief Strategy & Innovation Officer.
“Belgium is a leader in the application of new technologies to make precision healthcare a reality. Through this new study, we want to ensure that patients across Belgium can receive the right treatment for their particular cancer at the right time,” said Professor Dr Sylvie Rottey, Chair BSMO.
Dr Brigitte Maes of the Jessa Hospital in Belgium, Coordinator of BALLETT study said, “As part of Belgium’s broad approach to advancing precision medicine the study will generate valuable insights into the value of CGP versus currently reimbursed sequencing approaches. For example, in addition to genetic mutations that drive cancer formation, CGP will also identify cancers driven by the TMB biomarker which can guide patients towards immunotherapy treatments. This means that the study will give access to additional treatments which may not have been considered through more traditional diagnostic testing.”
Genomic data together with de-identified clinical data from the study will be used to populate a newly-established national genomic tumour database, collated with oversight from Belgium’s Scientific Institute for Public Health, Sciensano, designed to advance precision medicine and patients’ access to novel effective therapies.
OncoDNA is a theranostic and genomic company with renown expertise in precision oncology. The company provides comprehensive testing of cancer biomarkers (DNA, RNA and proteins) on solid and liquid biopsies as well NGS data interpretation services to oncologists, research institutes and biopharmaceutical companies across the globe. The company headquarters are based in Belgium, and its two entities – IntegraGen, a company specializing in the decryption of the human genome and Biosequence – are headquartered in France and Spain, respectively. The group employs approx. 115 employees in 9 countries, works with an international network of 35 distributors and collaborates with one European-based and one US-based subcontracted accredited laboratories. Connect with us on LinkedIn, Facebook.
Chief Product Officer